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We report the discovery and characterization of three conan­
tokin peptides from the venom of Conus parius. Each peptide 
(conantokin-Prl, -Pr2, and -Pr3) contains 19 amino acids with 
three y-carboxyglutamate (Gla) residues, a post-translationally 
modified amino acid characteristic of conantokins. The new 
peptides contain several amino acid residues that differ from 
previous conantokin consensus sequences. Notably, the new 
conantokins lack Gla at the 3rd position from the N terminus, 
where the Gla residue is replaced by either aspartate or by 
another post-translationally modified residue, 4-trans-ky- 
droxyproline. Conantokin-Pr3 is the first conantokin peptide to 
have three different post-translational modifications. Conan- 
tokins-Prl and -Pr2 adopt a-helical conformations in the pres­
ence of divalent cations (Mg2+ and Ca2+) but are generally 
unstructured in the absence of divalent cations. Conantokin- 
Pr3 adopts an a-helical conformation even in the absence of 
divalent cations. Like other conantokins, the new peptides 
induced sleep in young mice and hyperactivity in older mice 
upon intracranial injection. Electrophysiological assays con­
firmed that conantokins-Prl, -Pr2, and -Pr3 are A?-methyl-n- 
aspartate (NMDA) receptor antagonists, with highest potency 
for NR2B-containing NMDA receptors. Conantokin-Pr3 dem­
onstrated ~  10-fold selectivity for NR2B-containing NMDA  
receptors. However, conantokin-Pr2 showed minimal differ­
ences in potency between NR2B and NR2D. Conantokins-Prl, 
-Pr2, and -Pr3 all demonstrated high specificity of block for 
NMDA receptors, when tested against various ligand-gated ion 
channels. Conus parius conantokins allow for a better definition 
of structural and functional features of conantokins as ligands 
targeting NMDA receptors.
Most families of peptides extracted from the venoms of 
marine cone snails (genus Conus) are known as conotoxins; 
these peptides have an unusually high density of disulfide cross­
links. In contrast, the conantokins, which are also Conus venom
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peptides, typically lack disulfide bonds but characteristically 
contain several residues of an unusual post-translationally 
modified amino acid, y-carboxyglutamate (Gla).2 Conantokins 
were first identified by their ability to cause sleep in young mice 
and hyperactivity in older mice when injected intracranially (1 , 
2). Subsequently, they were characterized as antagonists of the 
A/r-methyl-D-aspartate (NMDA) receptor class of ionotropic 
glutamate receptors (3-5). The first conantokin peptide puri­
fied from the venom of Conus geographus, conantokin-G (con­
G), was reported over 20 years ago (1). However, in the ensuing 
decades only three additional conantokin peptides have been 
reported in the scientific literature as follows: conantokin-T 
(con-T) (3), conantokin-R (con-R) (6), and conantokin-L 
(con-L) (7); see Table 1 for a comparison of conantokin 
sequences.
The characterization of con-G demonstrated that it is a 
selective antagonist of N M D A  receptors containing the NR2B 
subunit (8). This pharmacological selectivity has raised general 
interest in several potential clinical applications that include 
developing conantokin peptides as drugs for neuroprotection 
(e.g. after ischemic stroke) (9-11), pain (12-14), epilepsy (3, 6, 
7,15), and probing mechanisms of drug addiction (16). Con-G 
(CGX-1007, Cognetix, Inc.) has reached phase I clinical trials 
for both pain and epilepsy (14).
In this work, we have identified three peptides that belong to 
the conantokin family from the venom of the Indo-Pacific fish- 
hunting cone snail species, Conus parius. We report the purifi­
cation, synthesis, and characterization of these conantokin 
peptides. In all previous cases, only a single conantokin peptide 
was purified and characterized from the venom of any particu­
lar Conus species. The characterization of these novel peptides 
significantly expands the body of knowledge regarding the 
conantokin family. The C. parius conantokins contain several 
amino acids that vary from consensus sequences of previously 
characterized conantokins, including novel post-translational 
modifications. Consequently, these peptides allow us to better 
define significant biochemical features of conantokins for tar­
geting N M D A  receptors.
1 The abbreviations used are: Gla, y,y-carboxyglutamate; ACN, acetonitrile; 
con, conantokin; Hyp, 0,4-frans-hydroxyproline; MALDI, matrix-assisted 
laser desorption ionization; NMDA, /V-methyl-D-aspartate; HPLC, high per­
formance liquid chromatography; nAChR, nicotinic acetylcholine receptor.



























Preparation o f Venom Extract—Venom ducts of C. parius 
were dissected from the cone snails as described previously 
(17). The collected venom ducts were lyophilized and stored at 
—80 °C. Fifteen lyophilized venom ducts were ground over liq­
uid nitrogen with mortar and pestle. Venom was extracted 
sequentially with 5 ml of H 20 , 3 ml each of 2096 acetonitrile 
(ACN), 4096 ACN, and 60% ACN. The venom suspension was 
sonicated in the extracting solvent five times in 30-s intervals at
0 °C and then centrifuged at 5000 X g  for 5 min. The combined 
supernatant (crude venom extract) was lyophilized and stored 
at —20 °C until further purification.
Peptide Purification-—-The crude venom extract was resus­
pended in a mixture of 0.1% trifluoroacetic acid (solvent A) and 
0.08596 trifluoroacetic acid in 90% ACN (solvent B) and applied 
into a Vydac Clg analytical column (4.6 X 250 mm, 5 /xm par­
ticle size). Peptides were eluted with a gradient of ACN using 
solvents A and B. The effluents were monitored at 220 nm. 
Individual peptides from various peaks were further purified by 
analytical HPLC runs. Each peptide solution was lyophilized 
and stored at —20 °C.
Peptide Sequencing-—-One. nmol of each of the purified pep­
tides was separately dissolved in 500 /xl of a mixture of 809-6 
solvent A and 2096 solvent B. The pH was adjusted to 7.5 with 
0.5 m  Tris base, and dithiothreitol was then added to a final 
concentration of 10 m M . The solution was flushed with argon, 
incubated for 20 min at 65 °C, and cooled to room temperature. 
Two microliters of 4-vinylpyridine were added to the solution, 
which was placed in the dark at room temperature for 25 min. 
The peptide solution was then diluted with 500 /xl of solvent A 
and applied into a Clg analytical column. The purified alkylated 
peptide was sequenced by automated Edman degradation (18) 
on an Applied Biosystem model 492 sequenator, courtesy of Dr. 
Robert Schackmann of the DNA/Peptide Facility, University of 
Utah. The phenylthiohydantoin-derivatives were purified by 
analytical HPLC.
Peptide Synthesis—Based on peptide sequences, three pep­
tides were identified as conantokins. The conantokin peptides 
were synthesized using standard A/r-(9-fluorenyl)methoxycar- 
bonyl (Fmoc)-protected amino acids in an ABI model 430A 
peptide synthesizer, courtesy of Dr. Scott Endicott of the DNA/ 
Peptide Facility, University of Utah. After synthesis, each pep­
tide was cleaved from 20 mg of resin by treatment with 1 ml of 
a mixture of trifluoroacetic acid/H20/l,2-ethanedithiol/phe- 
nol/thioanisole (82.5/5/2.5/5/5 by volume) with agitation for
1 h at room temperature. The mixture was filtered under vac­
uum into methyl-£er£-butyl ether at —10 °C. Linear peptide was 
collected by centrifugation at 5000 X g  for 5 min, washed with 
methyl-£er£-butyl ether, and centrifuged again. The pellet was 
dissolved in 2096 ACN in 0.196 trifluoroacetic acid and applied 
into a Vydac Clg semi-preparative column (10 X 250 mm, 
5-/xm particle size). Elution was carried out at 5 ml/min using a 
gradient of solvent B.
Mass Spectrometry—-Matrix-assisted laser desorption ioniza­
tion (MALDI) mass spectra were obtained using a Voyager GE 
STR mass spectrometer at the Mass Spectrometry and Pro- 
teomic Core Facility of the University of Utah.
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Molecular Cloning— cDNA was prepared by reverse tran­
scription of RNA isolated from a C. parius venom duct as 
described previously (19). This cDNA was used as a template 
for PCR with oligonucleotides corresponding to the conserved 
signal sequence and 3'-untranslated region sequences of 
conantokin prepropeptides. The resulting PCR products were 
purified using the high pure PCR product purification kit 
(Roche Diagnostics) following the manufacturer’s suggested 
protocol. The eluted DNA fragments were annealed to pAMPl 
vector, and the resulting products were transformed into com­
petent DH5a cells, using the CloneAmp pAMP system for 
rapid cloning of amplification products (Invitrogen) following 
the manufacturer’s suggested protocols. The nucleic acid 
sequences of the resulting conantokin encoding clones were 
determined according to the standard protocol for automated 
sequencing.
Bioassay—-Mice were injected intracranially with 20 /xl of pep­
tide in normal saline solution using a syringe with 29-gauge needle 
according to the method described earlier (20). Mice injected 
intracranially with an equal volume of normal saline solution 
served as negative controls. After injection, the mice were placed 
in cages for observation.
Circular Dichroism Spectroscopy—CD data were collected on 
an Aviv 62DS circular dichroism spectropolarimeter (instru­
ment belonging to Dr. Michael Kay, University of Utah). All 
measurements were taken at room temperature in a 0.1-cm 
path length cuvette between 200 and 250 nm. Peptides were 
dissolved at 90 /x m  final concentration in 10 m M  sodium phos­
phate buffer, pH 7.0, with or without 2 mM MgCl2. Peptides 
were separately dissolved at 90 /xm  final concentration in 10 m M  
HEPES buffer, pH 7.0, with or without 2 mM CaCl2. The molar 
ellipticity (0) was calculated by using the following equation: 
0 = (100 X (CD signal at 222 nm))/((n — 1) X L X (concentra­
tion of peptide in m M )) , where n =  number of residues in the 
peptide; L = pathlength of the cuvette in cm; and the CD signal 
is in millidegrees. The CD signal was adjusted by subtracting 
the CD signal for buffer solution alone from the CD signal for 
the solution containing peptide. Molar ellipticity of —40,000 
degrees cm2 dmol 1 was estimated to be a perfect a-helix 
(10096 a-helix). The percent helical conformation was calcu­
lated by assuming a linear relationship in comparison with 
10096 a-helix.
Heterologous Expression of Receptors in Xenopus Oocytes— 
The rat NM DA receptor clones used were N R l-3b , NR2A, 
NR2B, NR2C, and NR2D (GenBank1M accession numbers 
U08266, AF001423, U11419, U08259, and U08260, respec­
tively). Dr. Steven M. Sine, Mayo Clinic College of Medicine, 
provided the mouse muscle nAChR clones in the cytomegalo­
virus-based pRBG4 vector. Dr. Stephen F. Heinemann, The 
Salk Institute, provided rat neuronal nAChR clones. Human 
neuronal nAChR clones were provided by Dr. Jim Garrett, Cog- 
netix, Inc. a-Amino-3-hydroxy-5-methyl-4-isoxazole propio­
nate receptor clones were provided by Dr. Erin Meyer and Dr. 
A. Villu Maricq, University of Utah.
With the exception of GluR3 and the mouse muscle nAChR 
clones, all of the expression clones were used to make capped 
RNA for injection into the oocytes of Xenopus laevis frogs 
(most clones expressed genes from a T7 promoter). The har­




























v e s t i n g  o f  Xenopus o o c y t e s  w a s  d e s c r i b e d  p r e v i o u s l y  i n  d e t a i l  
( 2 1 ) .  C a p p e d  R N A  w a s  p r e p a r e d  u s i n g  in vitro R N A  t r a n s c r i p ­
t i o n  k i t s  f r o m  A m b i o n ,  I n c . ,  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s 
p r o t o c o l s .  F o r  e x p r e s s i o n  o f  N M D A  r e c e p t o r s  a n d  n e u r o n a l  
n A C h R s ,  t y p i c a l l y  5  n g  o f  e a c h  s u b u n i t  c a p p e d  R N A  w a s  
i n j e c t e d  p e r  o o c y t e .  F o r  e x p r e s s i o n  o f  s k e l e t a l  m u s c le  n A C h R s  
a n d  G lu R 3 ,  1 n g  o f  e a c h  s u b u n i t  c D N A  w a s  i n j e c t e d  i n t o  t h e  
n u c l e u s  o f  e a c h  o o c y t e .  T h e  p l a s m i d  c o n s t r u c t s  e n c o d in g  
m o u s e  m u s c le  n A C h R  s u b u n i t s  a n d  G lu R 3  c o n t a i n  g e n e s  
e x p r e s s e d  f r o m  a  c y t o m e g a l o v i r u s  p r o m o t e r .  O o c y t e  r e c o r d ­
in g s  w e r e  o b t a i n e d  1-6  d a y s  p o s t - i n j e c t i o n .
Electrophysiology—V o l t a g e  c l a m p  r e c o r d i n g  o f  Xenopus 
o o c y t e s  w a s  c o n d u c t e d  a s  d e s c r i b e d  i n  d e t a i l  p r e v i o u s l y  ( 21 ) . 
B r i e f l y ,  a l l  o o c y t e s  w e r e  v o l t a g e - c l a m p e d  a t  ^ 7 0  m V .  O o c y t e s  
e x p r e s s i n g  N j M D A  r e c e p t o r s  w e r e  g r a v i t y  p e r f u s e d  w i t h  M g 2 f -  
f r e e  N D 9 6  b u f f e r  ( 9 6 . 0  m M  N a C l ,  2 . 0  m M  K C l ,  1 .8  m M  C a C l 2 , 5  
m M  H E P E S ,  p H  7 . 2 - 7 . 5 ) .  M g C l 2 w a s  n o t  i n c l u d e d  i n  N D 9 6  
b u f f e r  u s e d  f o r  t e s t i n g  N j M D A  r e c e p t o r s  b e c a u s e  M g 2 +  b l o c k s  
N M D A  r e c e p t o r s .  F o r  a l l  o t h e r  e l e c t r o p h y s i o l o g i c a l  t e s t s ,  
o o c y t e s  w e r e  g r a v i t y  p e r f u s e d  w i t h  N D 9 6  b u f f e r  ( 9 6 . 0  m M  N a C l ,
2 . 0  m M  K C l ,  1 .8  m M  C a C l 2 , 1 m M  M g C l 2 , 5  m M  H E P E S ,  p H  
7 . 2 - 7 . 5 ) .  I n  a l l  c a s e s ,  b o v i n e  s e r u m  a l b u m i n  w a s  a d d e d  t o  b u f f e r  
a t  a  f i n a l  c o n c e n t r a t i o n  o f  0.1 m g / m l  t o  r e d u c e  n o n s p e c i f i c  
a d s o r p t i o n  o f  p e p t i d e .  C u r r e n t s  w e r e  e l i c i t e d  b y  1 - s  p u l s e s  o f  
g r a v i t y - p e r f u s e d  a g o n is t  s o l u t i o n  o n c e  p e r  m i n  o r  o n c e  p e r  2 
m i n ,  d e p e n d i n g  o n  t h e  r e c e p t o r  r e c o v e r y  f r o m  d e s e n s i t i z a t i o n .  
200 ixm g l u t a m a t e  a n d  20 ixm g l y c in e  w e r e  u s e d  a s  c o - a g o n is t s  
f o r  N M D A  r e c e p t o r s ;  1 0 - 2 0 0  ixm a c e t y l c h o l i n e  w a s  e m p lo y e d  
a s  t h e  a g o n i s t  f o r  t h e  v a r i o u s  n A C h R s .  B u f f e r  w a s  p e r f u s e d  c o n ­
t i n u o u s l y  o v e r  t h e  o o c y t e s  b e t w e e n  a g o n i s t  p u ls e s ,  w i t h  t h e  
e x c e p t i o n  o f  5 - 1 0 - m i n  e q u i l i b r a t i o n  p e r i o d s ,  d u r i n g  w h i c h  
b u f f e r  f l o w  w a s  h a l t e d  f o r  t h e  a p p l i c a t i o n  o f  a  p e p t i d e  t o  a n  
o o c y t e  i n  a  s t a t i c  b a t h .  T o  i d e n t i f y  t h e  e f f e c t  o f  a  p e p t i d e  o n  t h e  
r e c e p t o r  h e t e r o l o g o u s l y  e x p r e s s e d  i n  a n  o o c y t e ,  t h e  a m p l i t u d e  
o f  t h e  e l i c i t e d  c u r r e n t  f o l l o w i n g  t h e  p e p t i d e  a p p l i c a t i o n  a n d  
e q u i l i b r a t i o n  p e r i o d  w a s  c a l c u la t e d  a s  a  p e r c e n t a g e  o f  t h e  
a m p l i t u d e  o f  t h e  e l i c i t e d  c u r r e n t  p r i o r  t o  t o x i n  a p p l i c a t i o n .  A l l  
d a t a  r e c o r d i n g s  w e r e  c o n d u c t e d  a t  r o o m  t e m p e r a t u r e .  D a t a  
a c q u i s i t i o n  w a s  a u t o m a t e d  b y  a  v i r t u a l  i n s t r u m e n t  m a d e  b y  
D o j u  Y o s h i k a m i  o f  t h e  U n i v e r s i t y  o f  U t a h .  C o n c e n t r a t i o n - r e -  
s p o n s e  c u r v e s  w e r e  g e n e r a t e d  u s in g  P r i s m  s o f t w a r e  ( G r a p h P a d  
S o f t w a r e ,  I n c . ) ,  w i t h  t h e  f o l l o w i n g  e q u a t i o n ,  w h e r e  n H  is  t h e  H i l l  
c o e f f i c i e n t  a n d  I C 50 is  t h e  c o n c e n t r a t i o n  o f  p e p t i d e  c a u s in g  h a l f -  
m a x i m a l  b l o c k :  %  r e s p o n s e  =  1 0 0 / { 1  +  ( [ p e p t i d e ] / I C 50) " " } .
RESULTS
Purification of Conantokins from C. parius Venom—O n e  
s t r a t e g y  e m p lo y e d  f o r  i d e n t i f y i n g  t h e  m o l e c u l a r  t a r g e t s  o f  
Conus p e p t i d e s  h a s  b e e n  t o  a s s e s s  H P L C - s e p a r a t e d  f r a c t i o n s  
f r o m  c r u d e  v e n o m  e x t r a c t s  f o r  b i o l o g i c a l  a c t i v i t y  u s i n g  a  b e h a v ­
i o r a l  a s s a y  o n  m ic e .  T h i s  a p p r o a c h  a l l o w e d  u s  t o  i s o la t e  t h r e e  
p e p t i d e s  f r o m  a  s in g le  v e n o m  p r e p a r a t i o n  o f  C . parius t h a t  a l l  
i n d u c e d  s le e p  i n  10- d a y - o l d  m ic e  w h e n  i n j e c t e d  i n t r a c r a n i a l l y .  
U s i n g  r e v e r s e - p h a s e  H P L C ,  t h e  c r u d e  v e n o m  e x t r a c t  g a v e  t h e  
e l u t i o n  p r o f i l e  s h o w n  i n  F ig .  I A .  T h r e e  p e a k s  c o n t a i n i n g  t h e  
s l e e p - i n d u c i n g  a c t i v i t i e s  w e r e  f u r t h e r  f r a c t i o n a t e d  t o  h o m o g e ­
n e i t y  a s  s h o w n  i n  F ig .  1 , B -K , g i v i n g  r i s e  t o  t h r e e  d i s t i n c t  p e p ­
t i d e s  d e s c r i b e d  b e l o w .
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FIGURE 1. Purification of conantokins. A Cla HPLC analytical column was 
used in each purification step with a gradient of solvent B using 0.1% triflu ­
oroacetic acid (solvent A) and 0.085% trifluoroacetic acid in 90% ACN (solvent 
B). The flow rate was 1 ml/min in each step. The arrow indicates the fraction 
containing the peptide. A  fractionation of C. parius crude venom extract pre­
pared as described under "Experimental Procedures" at 0-60%  solvent B for 
120 min. Sand C, purification of con-Pr1 from peak 1 in solvent A at 20-45%  
solvent B over 25 min in each step. D-G, purification of con-Pr2 from peak 2 in 
solvent A at 25-50% solvent B for 25 min, 25-75% solvent B for 20 min, 
20-70% solvent B for 20 min,and 20-70% solvent B for 20 min, respectively. 
H-K, purification of con-Pr3 from peak 3 in solvent A at 25-45% solvent B for 
20 min, 25-65% solvent B for 20 min, 25-65% solvent B for 20 min, and 
20-70% solvent B for 20 min, respectively.
E a c h  o f  t h e  p u r i f i e d  p e p t i d e s  w a s  r e d u c e d ,  a l k y la t e d ,  a n d  
s e q u e n c e d  a s  d e s c r i b e d  u n d e r  “ E x p e r i m e n t a l  P r o c e d u r e s ”  b y  
E d m a n  c h e m i c a l  a n a ly s is .  M A L D I  m a s s  s p e c t r o m e t r y  w a s  u s e d  
t o  c o n f i r m  t h e  m a s s e s ,  w h i c h  s h o w e d  m a s s e s  t h a t  d i f f e r e d  b y  4 4  
m a s s  u n i t s  f o r  t h e  t h r e e  p e p t i d e s ,  i n d i c a t i n g  t h e  p r e s e n c e  o f  G la  
r e s id u e s .
I n  F ig .  1 C ,  t h e  p u r i f i e d  p e p t i d e  h a s  1 9  a m i n o  a c i d  r e s id u e s  
w i t h  t h e  s e q u e n c e  G E D 7Y A 7G I R 7Y Q L I H G K I A  w h e r e  y  i n d i ­
c a t e s  G l a  a n d  t h e  a  i n d i c a t e s  f r e e  a c i d  C  t e r m i n u s .  M A L D I  m a s s  
s p e c t r o m e t r y  o f  t h e  p e p t i d e  g a v e  a v e r a g e  m a s s e s  o f  2 3 5 2 . 8 ,

















Novel C. parius Conantokins
Comparison of previously characterized conantokins w ith C parius conantokins
Con, conantokin; y ,y-carboxyglutamate; O, 4-£ra«s-hydroxyproline; *, C-terminal amidation; A, C-terminal free acid. Consensus sequences from 
previously characterized conantokins are underlined. Differences from the previous consensus in the newly characterized conantokins are in boldface type.
TABLE 1
C o n u s  S p e c ie s C o n a n to k in A m in o -A c id  S e q u e n ce R e f .
C. g e o g r a p h u s C on-G GE YY LQ y NQ i  L IR jy  KSN* (1)
C. l y n c e u s C o n -L GE YY VA K MAA Y LAR Y DAVN* (7)
C. r a d i a t u s C on-R GE YY VA K MAA I  LAR y NIAKGCKVNCYPA (6)
C. t u l i p a C o n -T GE YY YQ K ML Y NLR Y AEVKKNA* (3)
C. p a r i u s C o n - P r l GE Dy YA y G IR  y YQL I  H G K I/V T h is  w o rk
C. p a r i u s C o n -P r2 DE Oy YA y A IR  y YQL K Y G K I" T h is  w o rk





Nucleotides and predicted amino acids for conantokin sequences cloned from  C. parius venom-duct cDNA
C o n a n to k in N u c le o tid e - and P re d ic te d  A m in o -A c id  Sequences
C o n -P r2 D E P E Y A E A I R E Y Q L K Y G K I
GACGAACCCGAATATGCAGAAGCGATAAGAGAGTATCAACTTAAATATGGGAAAATA











1C injections o f 10-day-old Swiss-Webster mice
Peptide No. of No. o f mice Average onset
injected Dosage mice in sleep-like o f deep sleep
(or saline) injected state (Minutes)
nmol
Saline (—control) NA" 4 0 NA
Con-G (+  control) 5 4 4 3.9
1 4 4 10.0
0.5 4 2 10.5
Con-Prl 5 4 4 9.0
1 6 5 12.2
0.5 5 4 18.0
Con-Pr2 5 3 3 9.7
1 2 2 14.0
0.5 2 2 17.5
Con-Pr3 5 3 3 10.7
1 2 2 16.5
0.5 3 2 21.0
FIGURE 2. HPLC co-elution of native and synthetic conantokins. Elution 
was done with a gradient of 20 -70% solvent B (0.085% trifluoroacetic acid in 
90% acetonitrile) in each case. A, native con-Pr1; B, synthetic con-Pr1; 
C, native/synthetic con-Pr1; D, native con-Pr2; £  synthetic con-Pr2; F, native/ 
synthetic con-Pr2; 6, native con-Pr3; H, synthetic con-Pr3; I, native/synthetic 
con-Pr3.
2 3 0 9 . 4 ,  2 2 6 5 . 9 ,  a n d  2 2 2 2 . 2 ,  i n d i c a t i n g  t h e  d e c a r b o x y l a t i o n  o f  
t h e  t h r e e  G l a  r e s id u e s ,  c o n s i s t e n t  w i t h  t h e  c a l c u l a t e d  m a s s  o f  
2 3 5 2 . 4  o f  t h e  i n t a c t  p e p t i d e .  T h e  p e p t i d e  w a s  r e f e r r e d  t o  a s  
c o n a n t o k i n - P r l  ( c o n - P r l ) .
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a NA means not applicable.
T h e  p u r i f i e d  p e p t i d e  i n  F ig .  1 G  i n c l u d e s  1 9  a m i n o  a c i d  r e s i ­
d u e s  a n d  h a s  t h e  s e q u e n c e  D E O y Y A y A I R y Y Q L K Y G K l A  
w h e r e  O  i n d i c a t e s  4 - £ r a n s - h y d r o x y p r o l i n e  ( H y p ) .  B a s e d  o n  
M A L D I  m a s s  s p e c t r o m e t r y ,  t h e  p e p t i d e  h a s  a v e r a g e  m a s s e s  o f  
2 4 6 2 . 8 ,  2 4 1 9 . 2 ,  2 3 7 5 . 4 ,  a n d  2 3 3 1 . 3 ,  i n  a g r e e m e n t  w i t h  t h e  c a l ­
c u l a t e d  m a s s  o f  2 4 6 3 . 6  o f  t h e  i n t a c t  p e p t i d e .  T h e  p e p t i d e  w a s  
d e s i g n a t e d  c o n a n t o k i n - P r 2  ( c o n - P r 2 ) .
F i g .  1 /C  s h o w s  a  h o m o g e n e o u s  p e a k  o f  t h e  p e p t i d e  c o n ­
t a i n i n g  1 9  a m i n o  a c i d  r e s i d u e s  w i t h  t h e  s e q u e n c e  G E O y -  
V A K W A y G L R y K A A S K P ,  w h e r e *  i n d i c a t e s  C - t e r m i n a l  a m i d a ­
t i o n .  T h e  a v e r a g e  m a s s e s  d e t e r m i n e d  b y  M A L D I  w e r e  2 1 8 9 . 6 ,  
2 1 4 6 . 2 , 2 1 0 2 . 7 ,  a n d  2 0 5 8 . 5  ( c a l c u l a t e d  m a s s  o f  t h e  i n t a c t  p e p ­
t i d e  =  2 1 8 9 . 2 ) .  T h e  p e p t i d e  w a s  n a m e d  c o n a n t o k i n - P r 3  
( c o n - P r 3 ) .
T h e  g e n e s  e n c o d i n g  t w o  o f  t h e s e  c o n a n t o k i n s  h a v e  b e e n  
c lo n e d ,  c o n f i r m i n g  t h e  s e q u e n c e s  a n d  i n d i c a t i n g  t h a t  t h e  p e p ­
t i d e s  b e l o n g  t o  t h e  c o n a n t o k i n  f a m i l y  ( T a b l e s  1 a n d  2 ) .  E a c h  o f  
t h e  t h r e e  p e p t i d e  s e q u e n c e s  i s o la t e d  w a s  u n i q u e  a n d  d i f f e r e n t



























FIGURE 3. Circular dichroism spectroscopy of C. parius conantokins and con-G. In each case, the x  axis is wavelength of UV light (200-250 nm), and they 
axis is the CD signal in millidegrees. Dual minima at 208 and 222 nm are characteristic of a-helix.The%a-helix is shown in the lower right comer of each boxand 
was estimated as described under "Experimental Procedures." The top two rows show the raw circular dichroism data for each peptide in 10 mivi phosphate 
buffer, pH 7, either in the presence or absence of 2 miviMgCI2.The bottom two rows showtherawcircular dichroism data for each peptide in 10 mivi HEPES buffer, 
pH 7, either in the presence or absence of 2 mivi CaCI2.
f r o m  a l l  p r e v i o u s l y  c h a r a c t e r i z e d  c o n a n t o k i n s .  T h u s ,  f u r t h e r  
i n - d e p t h  c h a r a c t e r i z a t i o n  o f  t h e s e  p e p t i d e s  w a s  u n d e r t a k e n  a t  
t h i s  p o i n t .
Peptide Synthesis— C o n - P r l ,  - P r 2 ,  a n d  - P r 3  w e r e  s y n t h e s i z e d  
o n  s o l i d  s u p p o r t  a s  d e s c r i b e d  u n d e r  “ E x p e r i m e n t a l  P r o c e ­
d u r e s . ”  M a s s  s p e c t r o m e t r y  c o n f i r m e d  t h a t  n a t i v e  a n d  s y n t h e t i c  
p e p t i d e s  h a d  t h e  s a m e  m a s s e s .  I n  e a c h  c a s e ,  a n  H P L C  f r a c t i o n  
o f  s y n t h e t i c  p e p t i d e  t h a t  e l u t e d  w i t h  t h e  s a m e  r e t e n t i o n  t i m e  a s  
t h e  n a t i v e  p e p t i d e  a l s o  c o - e l u t e d  w i t h  t h e  n a t i v e  p e p t i d e  w h e n  
e q u a l  q u a n t i t i e s  o f  n a t i v e  a n d  s y n t h e t i c  p e p t i d e  w e r e  e o - i n -  
j e c t e d  i n t o  a n  H P L C  c o l u m n  ( F ig .  2 ) .  T h e  p e p t i d e  s e q u e n c in g ,
DECEMBER 21, 2007-VQLUME 282-NUMBER 51 a&j&fe
m o l e c u l a r  c l o n i n g ,  m a s s  s p e c t r o m e t r y ,  a n d  H P L C  c o - e l u t i o n  
d a t a  a l l  i n d i c a t e  t h a t  t h e  n a t i v e  a n d  s y n t h e t i c  c o n a n t o k i n  p e p ­
t i d e s  a r e  c h e m i c a l l y  i d e n t i c a l .
In Vivo Biological Activities— A l l  t h r e e  c o n a n t o k i n s  ( e o n -  
P r l ,  - P r 2 ,  a n d  - P r 3 )  i n d u c e d  a  s le e p - l i k e  s t a t e  i n  1 0 - d a y - o l d  
m i c e  a n d  h y p e r a c t i v i t y  ( c o n t i n u o u s  w a l k i n g ,  e x c e s s iv e  g r o o m ­
in g ,  a n d  c l i m b i n g  o f  c a g e  w a l l )  i n  2 4 - d a y - o l d  m ic e ,  c h a r a c t e r i s ­
t i c  o f  k n o w n  c o n a n t o k i n s  ( 1 ,  3 ,  7 ) .  A n  i n i t i a l  s c r e e n  o f  t h e  v e n ­
o m - p u r i f i e d  c o n a n t o k i n s  i n d i c a t e d  t h a t  1  n m o l  o f  e a c h  
c o n a n t o k i n  i n j e c t e d  i n t r a e r a n i a l l y  i n t o  10 - d a y - o l d  m i c e  ( 6.8 ­
7 . 2  g )  i n d u c e d  l i g h t  s le e p  ( e a s i l y  a w a k e n e d  w i t h  a  t o u c h ) ,  w h i c h



























Novel C. parius Conantokins 
A
FIGURE 4. Current traces from NR1-3b/NR2B NMDA receptors expressed in Xenopus oocytes. Current 
traces in each panel were obtained sequentially (/eft to  right) as described under "Experimental Procedures." 
A, two current traces were obtained to establish a base line for current amplitude, followed by a 10-min buffer 
control, during which no peptide was added to the bath, but buffer flow was halted (static bath). After agonist 
pulses and buffer perfusion resumed (middle five current traces), it was evident that the base-line current 
amplitude had not changed significantly. After establishing that control, 1 /am con-Pr1 was applied to the 
oocyte in a static bath for 10 min. The first agonist-elicited current trace following the application of con-Pr1 
indicated that the elicited current was blocked nearly completely by the peptide, which began to dissociate 
from the receptor and wash out upon resumption of buffer perfusion (final three current traces). The current 
traces above the arrows show an expanded view of 15 s of each trace directly below the arrow, demonstrating 
the shape of each current trace. B, the same protocol as in A was followed, using con-G which served as a 
positive control for block of NR2B-containing NMDA receptors.
s le e p  s t a t e  w h e r e  t h e y  w o u l d  n o t  
r o l l  o v e r  o r  s t r u g g l e  u p o n  b e i n g  
r o l l e d  o n t o  t h e i r  b a c k s .  W e  h a v e  
n o t  p r o v i d e d  a  q u a n t i t a t i v e  a s s e s s ­
m e n t  o f  t h e  h y p e r a c t i v i t y  i n d u c e d  
i n  o l d e r  m i c e  b e c a u s e  t h e  o n s e t  o f  
h y p e r a c t i v i t y  w a s  d i f f i c u l t  t o  i d e n t i f y  
w i t h  p r e c i s i o n ,  a n d  t h e  h y p e r a c ­
t i v i t y  ( c o n t i n u o u s  w a l k i n g ,  e x c e s ­
s iv e  g r o o m i n g  a n d  c l i m b i n g  o f  c a g e  
w a l l )  t e n d e d  t o  b e  i n t e r r u p t e d  b y  
p e r i o d s  o f  s le e p .
Circular Dichroism Spectroscopy—  
B e c a u s e  c o n - P r l ,  - P r 2 ,  a n d  - P r 3  a l l  
s h a r e d  c o m m o n  c h a r a c t e r i s t i c s  o f  
c o n a n t o k i n s ,  w e  h y p o t h e s i z e d  t h a t  
t h e y  w o u l d  b e  s t r u c t u r a l l y  r e la t e d  t o  
c o n - G ,  w h i c h  a d o p t s  a n  a - h e l i c a l  
c o n f o r m a t i o n  i n  s o l u t i o n  i n  t h e  
p r e s e n c e  o f  d i v a l e n t  c a t io n s .  H o w ­
e v e r ,  i t  is  n e a r l y  s t r u c t u r e le s s  i n  t h e  
a b s e n c e  o f  d i v a l e n t  c a t i o n s  ( 2 2 ) .  T o  
e s t im a t e  t h e  a - h e l i c a l  c o n t e n t  o f  t h e  
C. parius c o n a n t o k i n s ,  c i r c u l a r  d i ­
c h r o i s m  s p e c t r o s c o p y  w a s  e m p lo y e d .  
T h e  a - h e l i c a l  c o n t e n t  o f  c o n - P r l  
a n d  - P r 2  w a s  e s t im a t e d  t o  b e  m u c h  
g r e a t e r  i n  t h e  p r e s e n c e  o f  M g i +  o r  
C a 2 +  t h a n  i n  t h e  a b s e n c e  o f  d i v a l e n t  
c a t i o n s ,  l i k e  c o n - G  ( F ig .  3 ) .  T h e  e s t i ­
m a t e d  a - h e l i c a l  c o n t e n t  o f  c o n - G  
( a s  a  c o n t r o l ) ,  c o n - P r l ,  a n d  c o n - P r 2  
w a s  g r e a t e r  i n  t h e  p r e s e n c e  o f  2 m M  
M g i +  t h a n  2  m M  C a 2 + , c o n s i s t e n t
e v e n t u a l l y  p r o g r e s s e d  t o  d e e p  s le e p .  T h e  t h r e e  c o n a n t o k i n s  i n i ­
t i a l l y  a p p e a r e d  t o  b e  a l m o s t  e q u a l l y  p o t e n t  i n  i n d u c i n g  s le e p  
w i t h  o n s e t  t i m e s  o f  l i g h t  s le e p  — 9 - 1 1  m i n  a f t e r  i n j e c t i o n .  T w o  
n m o l  o f  e a c h  c o n a n t o k i n  i n  2 4 - d a y - o l d  m ic e  ( 1 2 . 2 - 1 2 . 8  g )  g e n ­
e r a l l y  c a u s e d  h y p e r a c t i v i t y  w i t h i n  — 5 - 8  m i n  f r o m  i n j e c t i o n  
t i m e  l a s t i n g  f o r  — 4 0  m i n .  N a t i v e  a n d  s y n t h e t i c  p e p t i d e s  d e m ­
o n s t r a t e d  t h e  s a m e  b i o l o g i c a l  a c t i v i t y ,  c o n f i r m i n g  t h a t  n a t i v e  
a n d  s y n t h e t i c  p e p t i d e s  a r e  i d e n t i c a l .
W i t h  t h e  s y n t h e t i c  c o n a n t o k i n s ,  w e  e x p l o r e d  t h e  i n d u c t i o n  
o f  s le e p  i n  10 - d a y - o l d  m i c e  i n  m o r e  q u a n t i t a t i v e  d e t a i l ,  u t i l i z i n g  
c o n - G  a s  a  p o s i t i v e  c o n t r o l .  F o r  t h i s  a s s a y  ( s e e  T a b l e  3 ) ,  t h e  
o n s e t  o f  d e e p  s le e p  w a s  d e f i n e d  a s  t h e  t i m e  a t  w h i c h  m i c e  
w o u l d  n o  l o n g e r  a t t e m p t  t o  r o l l  t o  t h e i r  f e e t  a f t e r  b e i n g  r o l l e d  
o n t o  t h e i r  b a c k s .  S a l i n e - i n j e c t e d  n e g a t i v e  c o n t r o l s  a l w a y s  
r o l l e d  t o  t h e i r  f e e t  i m m e d i a t e l y  u p o n  b e i n g  r o l l e d  o n t o  t h e i r  
b a c k s .  A s  d e m o n s t r a t e d  i n  T a b l e  3 ,  h i g h e r  d o s a g e s  o f  e a c h  
c o n a n t o k i n  i n d u c e d  s le e p  m o r e  r a p i d l y  t h a n  l o w e r  d o s a g e s .  
I n  g e n e r a l ,  t h e  d u r a t i o n  o f  s le e p  a l s o  a p p e a r e d  t o  b e  a  f u n c ­
t i o n  o f  c o n a n t o k i n  d o s a g e ,  w i t h  l o n g e r  d u r a t i o n  o f  s le e p  
a s s o c i a t e d  w i t h  h i g h e r  d o s a g e s .  H o w e v e r ,  i t  w a s  d i f f i c u l t  t o  
q u a n t i f y  r e c o v e r y  t i m e  b e c a u s e  i n  m a n y  c a s e s ,  m i c e  i n j e c t e d  
w i t h  0 . 5 - 1 . 0  n m o l  o f  a  c o n a n t o k i n  w o u l d  p a r t i a l l y  r e c o v e r  
f r o m  t h e i r  s le e p  b u t  w o u l d  e v e n t u a l l y  r e t u r n  t o  t h e  d e e p -
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w i t h  t h e  p r e v io u s  o b s e r v a t i o n  t h a t  
c o n - G  h a s  h i g h e r  a f f i n i t y  f o r  M g i +  t h a n  C a 2 +  a n d  a  m o r e  d e f i n ­
i t i v e  s t r u c t u r e  i n  t h e  p r e s e n c e  o f  M g i +  t h a n  C a 2 +  ( 2 2 ) .  I n  c o n ­
t r a s t ,  c o n - P r 3  a d o p t e d  a  p r e d o m i n a n t l y  a - h e l i c a l  c o n f o r m a t i o n  
i n  b o t h  t h e  p r e s e n c e  a n d  a b s e n c e  o f  d i v a l e n t  c a t i o n s  ( F ig .  3 ) ,  
s i m i l a r  t o  c o n - T  ( 2 3 ) .
Electrophysiology— C o n s i d e r i n g  t h e i r  s e q u e n c e  a n d  s t r u c ­
t u r a l  s i m i l a r i t y  t o  o t h e r  c o n a n t o k i n s ,  w h i c h  a r e  k n o w n  t o  
i n h i b i t  N M D A  r e c e p t o r s ,  w e  t e s t e d  c o n - P r l ,  - P r 2 ,  a n d  - P r 3  
a g a in s t  r a t  N M D A  r e c e p t o r s  e x p r e s s e d  i n  Xenopus o o c y t e s .  I n  
e a c h  c a s e ,  w e  e x p r e s s e d  t h e  N R l - 3 b  s p l i c e  v a r i a n t  w i t h  o n e  
N R 2  s u b u n i t  ( A - D ) .  B e c a u s e  c o n - G  is  r e p o r t e d  t o  i n h i b i t  s e le c ­
t i v e l y  N M D A  r e c e p t o r s  e x p r e s s i n g  t h e  N R 2 B  s u b u n i t ,  w e  u s e d  
c o n - G  a s  a  c o n t r o l  f o r  o u r  e x p e r i m e n t s .
T o  s im u l a t e  s y n a p t i c  n e u r o t r a n s m i s s i o n ,  w h e r e  h i g h  c o n ­
c e n t r a t i o n s  o f  n e u r o t r a n s m i t t e r  a r e  r e le a s e d  t r a n s i e n t l y  a n d  
t h e n  r a p i d l y  c le a r e d  f r o m  t h e  s y n a p t i c  c l e f t ,  w e  e m p lo y e d  t h e  
e l e c t r o p h y s i o l o g i c a l  p r o t o c o l  d e s c r i b e d  u n d e r  “ E x p e r i m e n t a l  
P r o c e d u r e s ”  f o r  t e s t i n g  t h e  c o n a n t o k i n  p e p t i d e s .  A s  s h o w n  i n  
F ig .  4 , 1  /a m  c o n c e n t r a t i o n  o f  c o n - P r l  b l o c k e d  m o s t  o f  t h e  c u r ­
r e n t  e l i c i t e d  f r o m  v o l t a g e - c l a m p e d  Xenopus o o c y t e s  e x p r e s s i n g  
t h e  r a t  N R l - 3 b / N R 2 B  N M D A  r e c e p t o r ,  s i m i l a r  t o  c o n - G .  U t i ­
l i z i n g  t h e  s a m e  e l e c t r o p h y s i o l o g i c a l  p r o t o c o l  e m p l o y e d  i n  F ig .  
4 ,  e o n e e n t r a t i o n - r e s p o n s e  c u r v e s  w e r e  g e n e r a t e d  f o r  c o n - P r l ,




























FIGURE 5. Concentration-response curves for C. parius conantokins and con-G. Various NMDA NR2 sub­
units were separately co-expressed with NR1-3b in Xenopus oocytes. The electrophysiology protocol 
described in Fig. 4 and under "Experimental Procedures" was employed to test various concentrations of each 
peptide against the different subunit combinations. Percent-response values and concentration-response 
curves were determined as described under "Experimental Procedures" (n =- 3 tests for each data point).
TABLE 4
Approximate IC50 values for conantokins tested against various 
NR2 subunits
All data were obtained  from the concentration-response tu rves in Fig. 5, with the 














jLUf jLUf jLUf jLUf
Con-Prl > >10 0.2 >10 1 5 » 1 0
Con-Pr2 > >10 0.5 >10 1 2 » 1 0
Con-Pr3 > >10 0.5 >10 8 16 >10
Con-G > >10 0.1 1 1 10 » 1 0
Con-R 1 1 7 » 1 0 » 1 0 « 0.1
- P r 2 ,  - P r 3 ,  a n d  - G  f o r  a l l  N R 2  s u b u n i t s  i n  c o m b i n a t i o n  w i t h  t h e  
N R l - 3 b  s p l i c e  v a r i a n t  ( F ig .  5 ) .  A l l  o f  t h e s e  c o n a n t o k i n s  i n h i b ­
i t e d  t h e  N R 2 B - s u b u n i t - e o n t a i n i n g  r e c e p t o r s  w i t h  h i g h e s t  r e l a ­
t i v e  p o t e n c y  ( F ig .  5  a n d  T a b le  4 ) .  A l t h o u g h  c o n - P r l  a n d  - P r 2  
a l s o  i n h i b i t e d  N R 2 D - e o n t a i n i n g  r e c e p t o r s  w i t h  r e l a t i v e l y  h i g h  
p o t e n c y ,  c o n - P r 3  d e m o n s t r a t e d  — 1 0 - f o l d  s e l e c t i v i t y  f o r  N R 2 B ,  
s i m i l a r  t o  c o n - G  i n  o u r  h a n d s .  T o  d e t e r m i n e  t h e i r  s e l e c t i v i t y  f o r  
N j M D A  r e c e p t o r s ,  w e  t e s t e d  e a c h  o f  t h e s e  p e p t i d e s  a g a in s t  v a r ­
i o u s  l i g a n d - g a t e d  i o n  c h a n n e ls .  B a s e d  o n  t h i s  t e s t i n g ,  e a c h  o f  
t h e  p e p t i d e s  a p p e a r s  t o  b e  s p e c i f i c  f o r  N j M D A  r e c e p t o r s .  A t  1 0  
fjLM c o n c e n t r a t i o n ,  e a c h  p e p t i d e  f a i l e d  t o  i n h i b i t ,  o r  m i n i m a l l y
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i n h i b i t e d ,  c u r r e n t s  e l i c i t e d  f r o m  
n i c o t i n i c  a c e t y l c h o l i n e  r e c e p t o r s  o r  
n o n - N M D A  g l u t a m a t e  r e c e p t o r s  
( F ig .  6) .
DISCUSSION
P r e v i o u s  d i s c o v e r y  w o r k  o n  
c o n a n t o k i n s  y i e l d e d  a  s in g le  p e p t i d e  
b e l o n g i n g  t o  t h e  c o n a n t o k i n  f a m i l y  
f r o m  e a c h  i n d i v i d u a l  Conus v e n o m  
e x a m i n e d .  H o w e v e r ,  f r o m  t h e  
v e n o m  o f  C . parius t h r e e  d i f f e r e n t  
c o n a n t o k i n s  w e r e  i d e n t i f i e d  a n d  
c h a r a c t e r i z e d .  T h i s  w o r k  h a s  s i g n i f ­
i c a n t l y  e x p a n d e d  t h e  n u m b e r  o f  
c o n a n t o k i n  p e p t i d e s  r e p o r t e d  i n  t h e  
s c i e n t i f i c  l i t e r a t u r e  a n d  h a s  c o n t r i b ­
u t e d  t o  o u r  k n o w le d g e  r e g a r d i n g  
c o n a n t o k i n  s t r u c t u r e - f u n c t i o n  r e l a ­
t i o n s h i p s .  T h e  t h r e e  n e w l y  d i s c o v ­
e r e d  p e p t i d e s ,  c o n - P r l ,  - P r 2 ,  a n d  
- P r 3 ,  i s o la t e d  f r o m  C . parius, r e v e a l  
p r i m a r y  a m i n o  a c i d  s e q u e n c e s  w i t h  
s o m e  g e n e r a l  s i m i l a r i t i e s  t o  p r e v i ­
o u s l y  c h a r a c t e r i z e d  c o n a n t o k i n s  
( 1 ,  3 ,  6, 7 ) ,  m o s t  n o t a b l y  t h e  p r e s ­
e n c e  o f  m u l t i p l e  G l a  r e s i d u e s  a n d  
t h e  a b s e n c e  o f  d i s u l f i d e  b o n d s .  
H o w e v e r ,  t h e s e  p e p t i d e s  v a r y  f r o m  
t h e  p r e v i o u s  c o n a n t o k i n  c o n s e n s u s  
s e q u e n c e  a t  s e v e r a l  p o s i t i o n s  ( T a b l e  
1 ) ,  s u g g e s t i n g  t h a t  t h e  c o n a n t o k i n  
f a m i l y  is  m o r e  s t r u c t u r a l l y  a n d  
f u n c t i o n a l l y  d i v e r s e  t h a n  p r e v i o u s l y  
t h o u g h t .
I n  c o n t r a s t  t o  t h e  p r e v i o u s  c o n a n t o k i n  c o n s e n s u s  s e q u e n c e ,  
a l l  o f  t h e  C . parius p e p t i d e s  l a c k  a  G la  r e s id u e  a t  t h e  3 r d  p o s i t i o n  
f r o m  t h e  N  t e r m i n u s ;  a  r e s id u e  o f  e i t h e r  A s p  o r  H y p  is  p r e s e n t  a t  
t h a t  p o s i t i o n .  C o n - P r l  a n d  - P r 2  l a c k  A r g  a n d  G la  r e s id u e s  a t  
p o s i t i o n s  1 3 - 1 4  o r  1 4 - 1 5 ,  w h e r e a s  c o n - P r 2  h a s  a n  N - t e r m i n a l  
A s p  r a t h e r  t h a n  G ly .  F u r t h e r m o r e ,  c o n - P r 3  is  t h e  f i r s t  e x a m p l e  
o f  a  c o n a n t o k i n  c o n t a i n i n g  t h r e e  d i f f e r e n t  p o s t - t r a n s l a t i o n a l  
m o d i f i c a t i o n s :  y - c a r b o x y g l u t a m a t e ,  4 - i r a w s - h y d r o x y p r o l i n e ,  
a n d  C - t e r m i n a l  a m i d a t i o n  ( T a b l e  1 ) .  B e c a u s e  a l l  c o n a n t o k i n  
p e p t i d e s  t a r g e t  N j M D A  r e c e p t o r s ,  t h e  b i o c h e m ic a l  c h a r a c t e r i s t i c s  
r e q u i r e d  f o r  t h e i r  f u n c t i o n a l i t y  h a v e  b e e n  f u r t h e r  e l u c i d a t e d  b y  
t h i s  w o r k .
C o n a n t o k i n s  a r e  k n o w n  f o r  C a 2 + -  a n d  jM g 2 + - i n d u c e d  c o n ­
f o r m a t i o n a l  c h a n g e s ,  w h e r e  t h e  d i v a l e n t  c a t i o n s  p r o d u c e  a - h e l -  
i c a l  c o n f o r m a t i o n s  f r o m  r e l a t i v e l y  u n s t r u c t u r e d  p e p t i d e s  ( 2 4 ,  
2 5 ) .  T h e  a - h e l i c a l  c o n t e n t  o f  c o n - P r l  a n d  - P r 2  in c r e a s e d  s u b ­
s t a n t i a l l y  i n  t h e  p r e s e n c e  o f  p h y s i o l o g i c a l l y  r e l e v a n t  c o n c e n t r a ­
t i o n s  o f  d i v a l e n t  c a t i o n s ,  s i m i l a r  t o  c o n - G  ( F ig .  3 )  ( 2 2 ) .  H o w ­
e v e r ,  c o n - P r 3  is  p r e d o m i n a n t l y  a - h e l i c a l  e v e n  i n  t h e  a b s e n c e  o f  
d i v a l e n t  c a t i o n s  ( F ig .  3 ) ,  s i m i l a r  t o  e o n - T  ( 2 3 ) .  C o n - G  a d o p t s  a n  
a - h e l i c a l  c o n f o r m a t i o n  a l o n g  t h e  e n t i r e  l e n g t h  o f  t h e  p e p t i d e  i n  
t h e  p r e s e n c e  o f  jM g 2 +  b e c a u s e  t h e  s id e  c h a i n s  o f  t h e  G la  r e s i ­
d u e s  c o o r d i n a t e  t h e  d i v a l e n t  c a t i o n s  a p p r o x i m a t e l y  a l o n g  o n e
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FIGURE 6. Selectivity testing o f C. parius conantokins and con-G against 
various ligand-gated ion channels. In each case, 10 jxm peptide was applied 
to oocytes expressing the various receptors as described under "Experimen­
tal Procedures." All conantokins blocked rat NR1-3b/NR2B NMDA receptors 
completely or nearly completely at 10 jxm. However, these conantokins 
appeared to have little or no effect on other non-NMDA receptors tested. All 
the non-NMDA receptors tested are subtypes of nicotinic acetylcholine 
receptors, w ith the exceptions of GluRI and GluR3, which are a-amino-3- 
hydroxy-5-methyl-4-isoxazole propionate-type glutamate receptors (n =* 3 
tests for each bar).
f a c e  o f  t h e  a - h e l i x .  S u b s t i t u t i n g  a  d i f f e r e n t  a m i n o  a c i d  f o r  a n y  
G la  r e s id u e  d e c r e a s e d  t h e  a - h e l i c a l  c o n t e n t  o f  c o n - G  ( 2 2 ) .  
B e c a u s e  c o n - G  c o n t a i n s  f i v e  G la  r e s id u e s ,  w h e r e a s  c o n - P r l  a n d  
- P r 2  o n l y  h a v e  t h r e e  G la  r e s id u e s ,  t h e  a - h e l i c a l  c o n t e n t  o f  c o n -  
P r l  a n d  - P r 2  is  le s s  t h a n  t h e  a - h e l i c a l  c o n t e n t  o f  c o n - G  i n  t h e  
p r e s e n c e  o f  M g 2 +  ( F ig .  3 ) .
T h e  f a c t  t h a t  c o n - P r 3  a n d  c o n - T  a r e  s u b s t a n t i a l l y  a - h e l i c a l  i n  
t h e  a b s e n c e  o f  d i v a l e n t  c a t i o n s  m a y  b e  a c c o u n t e d  f o r  b y  t h e  
p r e s e n c e  o f  a  L y s  r e s id u e  a t  t h e  7 t h  p o s i t i o n  f r o m  t h e  N  t e r m i ­
n u s ,  w h e r e a s  c o n - G ,  - P r l ,  a n d  - P r 2  h a v e  a  G l a  r e s id u e  a t  t h a t  
p o s i t i o n  ( T a b l e  1 ) .  W e  h y p o t h e s i z e  t h a t  t h e  p o s i t i v e l y  c h a r g e d  
s id e  c h a i n  o f  L y s  s t a b i l i z e s  t h e  a - h e l i c a l  c o n f o r m a t i o n  t h r o u g h  
f a v o r a b le  e l e c t r o s t a t i c  i n t e r a c t i o n s  w i t h  t h e  n e g a t i v e l y  c h a r g e d  
s id e  c h a i n s  o f  G la  r e s id u e s  t h a t  a l i g n  a l o n g  t h e  s a m e  f a c e  o f  t h e  
a - h e l i x ,  m o s t  l i k e l y  a t  p o s i t i o n s  4  a n d  1 0  f r o m  t h e  N  t e r m i n u s ,  
s i g n i f i c a n t l y  r e d u c i n g  t h e  r e q u i r e m e n t  o f  d i v a l e n t  c a t i o n s  f o r  
s t a b i l i z i n g  t h e  a - h e l i c a l  c o n f o r m a t i o n .  T h i s  h y p o t h e s i s  w a s  
p r e v i o u s l y  s u g g e s t e d  f o r  c o n - T  b y  o t h e r  r e s e a r c h e r s  w h o  d e m ­
o n s t r a t e d  t h a t  w h e n  L y s  a t  p o s i t i o n  7  w a s  r e p la c e d  b y  G la ,  t h e  
p e p t i d e  h a d  l o w  a - h e l i c a l  c o n t e n t  i n  t h e  a b s e n c e  o f  d i v a l e n t  
c a t io n s .  T h e y  p r o p o s e d  t h a t  G la  d e s t a b i l i z e s  t h e  a - h e l i x  i n  t h e  
a b s e n c e  o f  d i v a l e n t  c a t i o n s  t h r o u g h  e l e c t r o s t a t i c  r e p u l s i o n  o f  
t h e  o t h e r  n e g a t i v e l y  c h a r g e d  G la  s id e  c h a i n s  t h a t  w o u l d  a l i g n  
w i t h  G la  a t  p o s i t i o n  7  i n  a n  a - h e l i c a l  c o n f o r m a t i o n  ( 2 6 ) .
C o n - R  a l s o  c o n t a i n s  a  L y s  r e s id u e  a t  t h e  7 t h  p o s i t i o n  f r o m  t h e  
N  t e r m i n u s  ( T a b l e  1 ) .  H o w e v e r ,  i t s  s t r u c t u r a l  r e l a t i o n s h i p  t o  
t h e  o t h e r  c o n a n t o k i n s  is  u n i q u e  b e c a u s e  i t  c o n t a i n s  a  d i s u l f i d e  
b o n d  n e a r  t h e  C  t e r m i n u s .  A l t h o u g h  n a t i v e  c o n - R  w a s  e s t i ­
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m a t e d  t o  b e  le s s  t h a n  3 5 %  a - h e l i c a l ,  e v e n  i n  t h e  p r e s e n c e  o f  
d i v a l e n t  c a t i o n s ,  s e v e r a l  C - t e r m i n a l  t r u n c a t i o n s  o f  c o n - R  
in c r e a s e d  t h e  a - h e l i c a l  c o n t e n t  o f  c o n - R  i n  b o t h  t h e  a b s e n c e  
a n d  p r e s e n c e  o f  d i v a l e n t  c a t io n s .  S o m e  o f  t h e  C - t e r m i n a l  t r u n ­
c a t i o n s  w e r e  e s t im a t e d  t o  b e  s u b s t a n t i a l l y  a - h e l i c a l  i n  t h e  
a b s e n c e  o f  d i v a l e n t  c a t i o n s ,  e.g. 4 5 %  a - h e l i x  f o r  c o n - R  r e s id u e s
1 - 1 4  ( 2 7 ) .  T h i s  o b s e r v a t i o n  is  c o n s i s t e n t  w i t h  t h e  h y p o t h e s i s  
t h a t  t h e  L y s  r e s id u e  a t  p o s i t i o n  7  s t a b i l i z e s  t h e  a - h e l i c a l  c o n f o r ­
m a t i o n  i n  c o n a n t o k i n s  t h a t  l a c k  a  d i s u l f i d e  b o n d  i n  t h e  a b s e n c e  
o f  d i v a l e n t  c a t i o n s .  T h e r e  a r e  n o  s t r u c t u r a l  d a t a  a v a i la b le  f o r  
c o n - L ,  w h i c h  a l s o  c o n t a i n s  L y s  a t  p o s i t i o n  7 .
A l t h o u g h  c o n - T  w a s  f o u n d  t o  b e  s u b s t a n t i a l l y  a - h e l i c a l  i n  t h e  
a b s e n c e  o f  d i v a l e n t  c a t i o n s  ( — 5 0 % ) ,  t h e  p r e s e n c e  o f  d i v a l e n t  
c a t i o n s  in c r e a s e d  t h e  e s t im a t e d  a - h e l i c a l  c o n t e n t  ( — 8 0 % )  ( 2 3 ­
2 5 ) .  T h e r e f o r e ,  i t  is  p a r t i c u l a r l y  s u r p r i s i n g  t h a t  c o n - P r 3  a p p e a r s  
t o  b e  — 6 0 %  a - h e l i c a l  i n  b o t h  t h e  p r e s e n c e  a n d  a b s e n c e  o f  d i v a ­
l e n t  c a t i o n s  ( F ig .  3 ) .  O n e  p o s s i b le  e x p l a n a t i o n  f o r  t h i s  a p p a r e n t  
d i f f e r e n c e  b e t w e e n  p e p t i d e s  is  t h e  p r e s e n c e  o f  H y p  a t  t h e  3 r d  
p o s i t i o n  f r o m  t h e  N  t e r m i n u s  i n  c o n - P r 3 ,  w h i c h  m a y  f u r t h e r  
s t a b i l i z e  t h e  a - h e l i c a l  c o n f o r m a t i o n  i n  t h e  a b s e n c e  o f  d i v a l e n t  
c a t i o n s ,  i n  c o n j u n c t i o n  w i t h  L y s  a t  p o s i t i o n  7 .
D e s p i t e  s t r u c t u r a l  d i f f e r e n c e s ,  t h e  C . parius p e p t i d e s  a r e  
f u n c t i o n a l l y  s i m i l a r  t o  o t h e r  c o n a n t o k i n s ,  p a r t i c u l a r l y  c o n - G .  
L i k e  c o n - G ,  a l l  o f  t h e  C . parius c o n a n t o k i n s  i n d u c e  s le e p  i n  
y o u n g  m i c e  a n d  h y p e r a c t i v i t y  i n  o l d e r  m ic e .  F u r t h e r m o r e ,  t h e y  
a l l  i n h i b i t  N M D A  r e c e p t o r s  t h a t  c o n t a i n  a n  N R 2 B  s u b u n i t  w i t h  
h i g h e s t  e f f i c a c y .  I n  o u r  h a n d s ,  c o n - P r 3  e x h i b i t e d  s e l e c t i v i t y  f o r  
N R 2 B  t h a t  is  s i m i l a r  i n  m a g n i t u d e  t o  t h e  s e l e c t i v i t y  o f  c o n - G .  
A l l  o f  t h e  C . parius c o n a n t o k i n s ,  a s  w e l l  a s  c o n - G ,  a p p e a r  t o  b e  
s p e c i f i c  f o r  N M D A  r e c e p t o r s ,  a s  t h e y  d i d  n o t  a f f e c t  a c t i v i t y  o f  
o t h e r  l i g a n d - g a t e d  i o n  c h a n n e ls .
C o n - P r 2  e x h i b i t e d  g r e a t e r  i n h i b i t i o n  o f  N R 2 D ,  r e l a t i v e  t o  
N R 2 B ,  t h a n  p r e v i o u s l y  c h a r a c t e r i z e d  c o n a n t o k i n s ,  a s  s h o w n  i n  
T a b l e  4 .  A l t h o u g h  t h e  b a s is  f o r  t h i s  l a c k  o f  s e l e c t i v i t y  b e t w e e n  
N R 2 B  a n d  N R 2 D  is  u n k n o w n ,  t h e r e  a r e  s e v e r a l  p o s s i b i l i t i e s  t h a t  
m a y  b e  e x p l o r e d  i n  f u t u r e  s t u d ie s .  F o r  e x a m p l e ,  c o n - P r 2  is  t h e  
o n l y  k n o w n  c o n a n t o k i n  t o  c o n t a i n  A s p  a t  t h e  N  t e r m i n u s ,  
w h i c h  m a y  p l a y  a  r o l e  i n  t h e  r e l a t i v e l y  h i g h e r  p o t e n c y  f o r  N R 2 D .  
H o w e v e r ,  c o n - P r l  a l s o  a p p e a r s  t o  d i s c r i m i n a t e  le s s  b e t w e e n  
N R 2 B  a n d  N R 2 D  t h a n  e i t h e r  c o n - P r 3  o r  c o n - G  ( T a b l e  4 ) .  
A m o n g  o t h e r  s i m i l a r i t i e s  b e t w e e n  c o n - P r l  a n d  - P r 2  ( n o t  
s h a r e d  b y  c o n - P r 3  o r  - G ) ,  t h e y  c o n t a i n  a  T y r  a t  p o s i t i o n  5  f r o m  
t h e  N  t e r m i n u s ,  w h i c h  m a y  a l s o  p l a y  a  r o l e  i n  p o t e n c y  f o r  N R 2 D  
r e l a t i v e  t o  N R 2 B .
F o r  t h e  f i v e  p e p t i d e s  s h o w n  i n  T a b l e  4 ,  a l l  p e p t i d e s  h a v e  a  b ia s  
f o r  N R 2 B .  H o w e v e r ,  c o n - R  is  a  m o r e  p o t e n t  a n t a g o n i s t  o f  N R 2 A  
t h a n  N R 2 D ,  a s  d e t e r m i n e d  p r e v i o u s l y  ( 1 5 ) ,  a n d  c o n f i r m e d  b y  
u s ,  u s i n g  t h e  s a m e  e l e c t r o p h y s i o l o g i c a l  p r o t o c o l  e m p l o y e d  i n  
t h i s  w o r k  ( d a t a  n o t  s h o w n ) .  I n  c o n t r a s t ,  t h e  C . parius c o n a n ­
t o k i n s  a n d  c o n - G  a r e  m o r e  p o t e n t  a n t a g o n is t s  o f  N R 2 D  t h a n  
N R 2 A ,  a s  s h o w n  i n  F ig .  5  a n d  T a b l e  4 .  C u m u l a t i v e l y ,  t h e s e  d a t a  
p r o v i d e  a  c o n c r e t e  b a s is  f o r  e x p l o r i n g  t h e  s t r u c t u r a l  f e a t u r e s  i n  
c o n a n t o k i n  p e p t i d e s  t h a t  d e t e r m i n e  r e l a t i v e  p o t e n c y  o f  b l o c k  
f o r  N R 2 A  versus N R 2 D .
T h e  e m e r g in g  s t r u c t u r a l  d i v e r s i t y  o f  c o n a n t o k i n s  is  l i k e l y  t o  
r e v e a l  m o r e  f u n c t i o n a l  d i v e r s i t y  a m o n g  c o n a n t o k i n  p e p t i d e s .  
C l e a r l y ,  t h e  c h a r a c t e r i z a t i o n  o f  m o r e  n a t i v e  c o n a n t o k i n  p e p -





















t i d e s  s h o u l d  r e v e a l  a d d i t i o n a l  s t r u c t u r a l  d e t e r m i n a n t s  t h a t  a r e  
i m p o r t a n t  f o r  s e l e c t i v i t y  b e t w e e n  N M D A  r e c e p t o r  s u b t y p e s .
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